Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Iloperidone (HP 873) is an atypical antipsychotic agent that is used for treatment of schizophrenia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 33.00 | |
10 mg | In stock | $ 50.00 | |
25 mg | In stock | $ 95.00 | |
50 mg | In stock | $ 165.00 | |
100 mg | In stock | $ 245.00 | |
200 mg | In stock | $ 363.00 | |
500 mg | In stock | $ 588.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 47.00 |
Description | Iloperidone (HP 873) is an atypical antipsychotic agent that is used for treatment of schizophrenia. |
Targets&IC50 | D3 receptor:7.1 nM(ki), D4 receptor:25 nM(ki) |
In vitro | Iloperidone displays high affinity (Ki < 10 nM) for norepinephrine alpha(1)-adrenoceptors, dopamine D(3) and serotonin 5-HT(2A) receptors. [1] Iloperidone displays higher affinity for the dopamine D3 receptor (Ki = 7.1 nM) than for the dopamine D4 receptor (Ki = 25 nM). Iloperidone displays high affinity for the 5-HT6 and 5-HT7 receptors (Ki = 42.7 nM and 21.6 nM, respectively), and is found to have higher affinity for the 5-HT2A (Ki = 5.6 nM) than for the 5-HT2C receptor (Ki = 42.8 nM). [2] Iloperidone significantly increases dopa accumulation, an index of dopamine turnover in response to D2 receptor blockade, at doses from 0.3 mg/kg to 10 mg/kg i.p. in the striatum and from 1 mg/kg to 10 mg/kg in the nucleus accumbens. [3] |
In vivo | Iloperidone exerts behavioral effects in pharmacological rats models of disrupted sensorimotor gating consistent with "atypical" antipsychotics, mediated by antagonism of dopaminergic and noradrenergic receptors. Iloperidone (1 and 3 mg/kg) prevents the PPI-disruptive effects of treatment with 1 mg/kg PCP. Iloperidone (0.3 mg/kg) prevents cirazoline-induced PPI deficits, independent of its effects on startle magnitude. [4] Iloperidone (10 mg/kg) and Melperone (10 mg/kg) produce an equivalent or a smaller increase in DA release in the nucleus accumbens (NAC) of rats, respectively, compared to the mPFC, whereas none of them increase acetylcholine (ACh) release in the NAC. [5] |
Kinase Assay | Immunoblotting for the mTOR kinase assay: HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr |
Synonyms | HP 873 |
Molecular Weight | 426.48 |
Formula | C24H27FN2O4 |
CAS No. | 133454-47-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 4 mg/mL (9.37 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 26 mg/mL (61 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Iloperidone 133454-47-4 GPCR/G Protein Neuroscience 5-HT Receptor Dopamine Receptor Adrenergic Receptor Inhibitor 5-hydroxytryptamine Receptor HP 873 atypical HP873 Serotonin Receptor inhibit symptoms HP-873 antipsychotic schizophrenia inhibitor